By Fineline Cube 
Qingfeng Pharmaceutical Group announced a strategic commercialization cooperation agreement with Vietnam’s TASCO PHARMA for the distribution of ten pharmaceutical products in the Vietnamese market. The partnership focuses on anti-tumor and central nervous system (CNS) therapeutic areas, aiming to enhance access to high-quality medicines for Vietnamese patients.
Partnership Structure
| Role | Entity | Responsibilities |
|---|---|---|
| Drug Filing Applicant & MAH | Qingfeng Pharmaceutical Group | Regulatory submissions, product registration, and market authorization |
| Exclusive Commercial Distributor | TASCO PHARMA | Import, promotion, marketing, and sales across Vietnam |
Product Portfolio Highlights
- Therapeutic Focus: Anti-tumor and Central Nervous System (CNS) medications
- Product Count: Ten established pharmaceutical products
- Market Strategy: Leverage complementary strengths to provide accessible and affordable treatment options
- Target Beneficiaries: Vietnamese healthcare providers and patients seeking quality oncology and neurological treatments
Strategic Rationale
The collaboration capitalizes on Qingfeng Pharma’s robust product pipeline and regulatory expertise as a Market Authorization Holder (MAH), combined with TASCO PHARMA’s extensive distribution network and local market knowledge in Vietnam. This partnership aligns with both companies’ missions to expand access to essential medicines in emerging markets.
Vietnam Pharmaceutical Market Context
- Market Size: Vietnam’s pharmaceutical market valued at approximately $7.5 billion in 2025, with projected 8-10% annual growth
- Oncology Demand: Rising cancer incidence rates driving increased demand for anti-tumor therapies
- CNS Treatment Gap: Limited access to advanced neurological medications creates significant unmet medical needs
- Regulatory Environment: Vietnam’s Ministry of Health has streamlined drug approval processes for imported medicines from qualified international manufacturers
Expected Impact & Timeline
- Implementation: Regulatory filings expected to commence within Q3 2026
- Market Entry: Initial product launches anticipated in H1 2027
- Patient Access: Partnership aims to reduce treatment costs by 15-25% compared to existing premium-priced alternatives
- Geographic Coverage: Nationwide distribution through TASCO PHARMA’s established hospital and retail pharmacy network
Forward‑Looking Statements
This brief contains forward-looking statements regarding partnership implementation, regulatory timelines, and market expectations. Actual results may differ due to risks including regulatory approvals, competitive dynamics, and market adoption rates.-Fineline Info & Tech